Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

551

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

May 31, 2017

Conditions
Community Acquired Pneumonia
Interventions
DRUG

lefamulin

antibacterial agent

DRUG

Moxifloxacin

antibacterial agent

DRUG

Linezolid

antibacterial agent

Trial Locations (99)

181

Site 5104, Pretoria

380

Site 5105, Thabazimbi

1000

Site 2003, Manila

1012

Site 2004, Manila

1050

Site 5101, Middelburg

1100

Site 2002, Quezon City

1114

Site 2001, Quezon City

1121

Site 4305, Budapest

1202

Site 4102, Sofia

1233

Site 4101, Sofia

Site 4106, Sofia

1500

Site 5103, Benoni

1606

Site 4110, Sofia

Site 4111, Sofia

1724

Site 5102, Krugersdorp

1900

Site 3005, La Plata

2045

Site 4303, Törökbálint

2300

Site 4112, Pernik

3529

Site 4307, Miskolc

Site 4308, Miskolc

3700

Site 4109, Vidin

4043

Site 4304, Debrecen

4700

Site 4108, Smolyan

5000

Site 4104, Veliko Tarnovo

Site 2005, Iloilo City

5300

Site 4105, Gabrovo

5500

Site 4107, Lovech

7002

Site 4103, Rousse

8582

Site 4302, Farkasgyepű

9300

Site 4306, Csorna

10002

Site 5206, Zhytomyr

10110

Site 2103, Nonthaburi

11000

Site 5002, Belgrade

11080

Site 5004, Kamenitz

18204

Site 5003, Niš

21105

Site 4801, Bucharest

Site 4806, Bucharest

34000

Site 5001, Kragujevac

40022

Site 5208, Sumy

41701

Site 1006, Hazard

44309

Site 1009, Akron

45402

Site 1002, Dayton

55415

Site 1005, Minneapolis

58005

Site 5203, Chernivtsi

59701

Site 1001, Butte

61124

Site 5201, Kharkiv

65025

Site 5211, Odesa

69035

Site 5212, Zaporizhzhia

69118

Site 5210, Zaporizhzhia

71103

Site 1008, Shreveport

72000

Site 4004, Zenica

73000

Site 5209, Kherson

75000

Site 4001, Tuzla

76018

Site 5204, Ivano-Frankivsk

77372

Site 1004, Splendora

88000

Site 4003, Mostar

150062

Site 4905, Yaroslavl

191163

Site 4903, Saint Petersburg

197706

Site 4901, Saint Petersburg

200515

Site 4803, Craiova

Site 4808, Craiova

214019

Site 4906, Smolensk

300310

Site 4807, Timișoara

Site 4809, Timișoara

454021

Site 4904, Chelyabinsk

630102

Site 4902, Novosibirsk

900002

Site 4802, Palazu Mare

S2000CVB

Site 3006, Rosario

X5000EPU

Site 3003, Córdoba

X5000JRD

Site 3007, Córdoba

X5004CDT

Site 3001, Córdoba

X5016KEH

Site 3004, Córdoba

30150-221

Site 3104, Belo Horizonte

99010-080

Site 3102, Passo Fundo

13059-900

Site 3103, Campinas

15090-000

Site 3101, Sao Paulo Do Rio Preto

0101

Site 4206, Tbilisi

0144

Site 4204, Tbilisi

Site 4205, Tbilisi

0159

Site 4201, Tbilisi

0186

Site 4202, Tbilisi

LV-5417

Site 4403, Daugavpils

LV-3414

Site 4401, Liepāja

LV-1038

Site 4402, Riga

7609 PP

Site 4603, Almelo

5707 HA

Site 4602, Helmond

Unknown

Site 3205, Trujillo

Lima 18

Site 3202, Lima

Lima 1

Site 3204, Lima

Lima 29

Site 3201, Lima

96-100

Site 4703, Skierniewice

02-097

Site 4704, Warsaw

90-153

Site 4701, Lódz

43-365

Site 4702, Wilkowice

030303

Site 4810, Bucharest

040000

Site 4811, Cluj-Napoca

03680

Site 5207, Kiyiv

Site 5205, Kyiv

01133

Site 5202, Kyiv

Sponsors
All Listed Sponsors
lead

Nabriva Therapeutics AG

INDUSTRY